Simplify Logo
Amgen

Amgen

Biotech company creating biologic medicines

Data Platform Lead - Information Systems

Full-TimeUpdated on 9/17/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person

About the job

Requirements
  • A Master's degree, or a Bachelor's degree in computer science or an engineering field, with 8 to 13 years of relevant experience.
  • Strong hands-on experience with Databricks capabilities spanning compute, storage, Unity Catalog, data engineering, business intelligence, and artificial intelligence/machine learning, with a focus on governance and enterprise enablement.
  • Hands-on experience with cloud platforms, preferably Amazon Web Services; Azure or Google Cloud Platform experience is also acceptable.
  • Experience leading data quality platform initiatives, including tool evaluation, implementation, enterprise-wide adoption, and integration with enterprise data quality solutions.
  • Experience owning and managing Databricks platform environments, including workspace architecture, development/test/production environment strategy, and lifecycle management at scale.
  • Ability to establish and enforce platform standards and operating models, including cluster policies, cost management, and workload orchestration frameworks.
  • Experience enabling platform adoption and developer experience through reusable frameworks, best practices, and support for engineering teams.
  • Exposure to artificial intelligence and machine learning capabilities on Databricks, including enabling AI-driven features or accelerating adoption of AI-assisted engineering practices.
  • Knowledge of SQL and relational and dimensional data modeling for platform integrations, governance, and observability use cases.
  • Experience with core Amazon Web Services services, including Elastic Kubernetes Service, Elastic Compute Cloud, Simple Storage Service, Lambda, Glue, Elastic MapReduce, Relational Database Service, and Redshift or Spectrum, particularly in platform or shared-services contexts.
  • Ability to design scalable, reusable solutions for complex data platform challenges.
  • Experience working in Agile delivery environments, with exposure to Jira or Jira Align.
  • Strong communication skills for articulating platform concepts, trade-offs, and best practices to senior technical and business stakeholders.
  • Ability to troubleshoot complex technical, governance, and integration challenges.
  • Experience working effectively across architecture, governance, platform, and delivery teams.
  • Ability to drive engineering excellence, platform maturity, and adoption outcomes.
  • Ability to manage multiple priorities while maintaining quality, reliability, and reusability.
  • Ability to plan, estimate, and deliver platform capabilities across multiple initiatives.
Responsibilities
  • Act as a platform lead for delivery of data platform capabilities that enable next-generation data platform architecture, focusing on Databricks and data quality platform features and services.
  • Evaluate and enable Databricks platform capabilities through technical assessments and proofs of concept, ensuring alignment with next-generation data platform architecture patterns and enterprise standards.
  • Design, build, and productionize reusable platform frameworks, accelerators, and reference implementations for next-generation data platform delivery teams.
  • Design and implement platform-level integrations between Databricks and Collibra to enable data governance, metadata-layer, and data-bundle capabilities.
  • Build platform-level tooling and automation supporting proactive governance, cost optimization, and best-practice enforcement across Databricks and related data platform services.
  • Define and enable platform observability capabilities, including key performance indicators, metrics, and telemetry for monitoring Databricks performance, usage, reliability, and cost.
  • Implement governed self-service platform capabilities for data engineers through a self-service portal using Python-based microservices deployed on Docker and Kubernetes.
  • Lead user enablement and adoption initiatives, including onboarding content, guided learning experiences, workshops, and best-practice sharing for the Databricks user community.
  • Drive engineering excellence and adoption of artificial intelligence across platform capabilities and solutions, promoting modern engineering practices, automation, and responsible use of AI-driven features.
  • Translate initiative-driven requirements into scalable, reusable data platform capabilities aligned with next-generation data platform principles.
  • Collaborate with Enterprise Data Architecture, governance, platform operations, and delivery teams to ensure platform capabilities are aligned, consumable, and enterprise-ready.
Desired Qualifications
  • Experience contributing to or enabling self-service platforms or portals, including front-end or API-driven portals and collaboration with front-end teams such as React-based portal teams.
  • Proficiency in Python-based microservices development, including designing and deploying application programming interfaces and services that enable platform capabilities.
  • Experience building platform application programming interfaces and services with Databricks software development kits and REST APIs for provisioning, managing, or governing Databricks environments, workspaces, clusters, jobs, users, permissions, and related platform features.
  • Experience with Ataccama or Monte Carlo data quality platforms used with data engineering platforms.
  • Familiarity with platform observability, telemetry, or cost-optimization patterns for large-scale data platforms.
  • Experience enabling data governance, metadata, or lineage integrations between data platforms and enterprise governance tools such as Collibra.
  • Experience with SQL, NoSQL, and vector databases, particularly for large language model-enabled or AI-assisted platform solutions.
  • Experience with continuous integration and continuous delivery pipelines, Docker containerization, and Kubernetes or Elastic Kubernetes Service for enterprise platform services.
  • Strong understanding of software engineering best practices, including version control, automated testing, continuous integration, and production-grade design.
  • AWS Certified Data Engineer certification.
  • Databricks certification.
  • SAFe Agile certification.
  • Ability to communicate technical platform concepts clearly to diverse audiences.
  • Experience working collaboratively across global teams and contributing to continuous improvement, modern engineering practices, and responsible AI adoption.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.